Melanoma Clinical Trial

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

Summary

RATIONALE: Diagnostic procedures may improve the ability to detect the presence or recurrence of disease.

PURPOSE: Diagnostic trial to detect melanoma markers in the lymph nodes or peripheral blood of patients who have melanoma.

View Full Description

Full Description

OBJECTIVES:

Determine the feasibility of performing reverse transcriptase-polymerase chain reaction (RT-PCR) for five different tumor antigen genes using lymph node samples or peripheral blood from patients with melanoma.
Determine the ability of PCR-positive lymph nodes or peripheral blood to predict relapse of disease in these patients.
Determine the correlation of positive PCR results from peripheral blood with disease stage.

OUTLINE: Lymph node biopsies or peripheral blood are obtained from patients. These specimens are examined by nested reverse transcriptase-polymerase chain reaction (RT-PCR) and analyzed for various tumor antigens.

Patients may choose to be told the results of this testing, but the results do not influence or change the planned therapy. Brief counseling is required to discuss the results and their potential implications.

Patients are followed for at least 2 years.

PROJECTED ACCRUAL: A total of 30 patients for the lymph node portion and 80 patients (20 per stage of disease) for the peripheral blood portion will be accrued for this study within 3 years.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Clinically proven melanoma with indication to perform sentinel lymph node biopsy or elective lymph node dissection OR
Histologically proven or diagnosis highly suspicious for melanoma

PATIENT CHARACTERISTICS:

Age:

Any age

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Platelet count greater than 50,000/mm^3
Hemoglobin greater than 7 g/dL

Hepatic:

PT less than 15 sec
PTT less than 30 sec

Renal:

Not specified

Other:

No psychiatric illness that precludes compliance
No other concurrent malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

Not specified

Surgery

Not specified

Study is for people with:

Melanoma

Estimated Enrollment:

106

Study ID:

NCT00004153

Recruitment Status:

Completed

Sponsor:

University of Chicago

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Chicago Cancer Research Center
Chicago Illinois, 60637, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

106

Study ID:

NCT00004153

Recruitment Status:

Completed

Sponsor:


University of Chicago

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider